RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers von Nichols, Robert J., Haderk, Franziska, Stahlhut, Carlos, Schulze, Christopher J., Hemmati, Golzar, Wildes, David, Tzitzilonis, Christos, Mordec, Kasia, Marquez, Abby, Romero, Jason, Hsieh, Tientien, Zaman, Aubhishek, Olivas, Victor, McCoach, Caroline, Blakely, Collin M., Wang, Zhengping, Kiss, Gert, Koltun, Elena S., Gill, Adrian L., Singh, Mallika, Goldsmith, Mark A., Smith, Jacqueline A. M., Bivona, Trever G.

Volltext

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer von Shah, Khyati N., Bhatt, Roma, Rotow, Julia, Rohrberg, Julia, Olivas, Victor, Wang, Victoria E., Hemmati, Golzar, Martins, Maria M., Maynard, Ashley, Kuhn, Jonathan, Galeas, Jacqueline, Donnella, Hayley J., Kaushik, Swati, Ku, Angel, Dumont, Sophie, Krings, Gregor, Haringsma, Henry J., Robillard, Liliane, Simmons, Andrew D., Harding, Thomas C., McCormick, Frank, Goga, Andrei, Blakely, Collin M., Bivona, Trever G., Bandyopadhyay, Sourav

Volltext

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer von McCoach, Caroline E, Blakely, Collin M, Banks, Kimberly C, Levy, Benjamin, Chue, Ben M, Raymond, Victoria M, Le, Anh T, Lee, Christine E, Diaz, Joseph, Waqar, Saiama N, Purcell, William T, Aisner, Dara L, Davies, Kurtis D, Lanman, Richard B, Shaw, Alice T, Doebele, Robert C

Volltext

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer von Blakely, Collin M., Pazarentzos, Evangelos, Olivas, Victor, Asthana, Saurabh, Yan, Jenny Jiacheng, Tan, Irena, Hrustanovic, Gorjan, Chan, Elton, Lin, Luping, Neel, Dana S., Newton, William, Bobb, Kathryn L., Fouts, Timothy R., Meshulam, Jeffrey, Gubens, Matthew A., Jablons, David M., Johnson, Jeffrey R., Bandyopadhyay, Sourav, Krogan, Nevan J., Bivona, Trever G.

Volltext

Inactivation of Capicua drives cancer metastasis von Okimoto, Ross A, Breitenbuecher, Frank, Olivas, Victor R, Wu, Wei, Gini, Beatrice, Hofree, Matan, Asthana, Saurabh, Hrustanovic, Gorjan, Flanagan, Jennifer, Tulpule, Asmin, Blakely, Collin M, Haringsma, Henry J, Simmons, Andrew D, Gowen, Kyle, Suh, James, Miller, Vincent A, Ali, Siraj, Schuler, Martin, Bivona, Trever G

Volltext

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins von Neel, Dana S, Allegakoen, David V, Olivas, Victor, Mayekar, Manasi K, Hemmati, Golzar, Chatterjee, Nilanjana, Blakely, Collin M, McCoach, Caroline E, Rotow, Julia K, Le, Anh, Karachaliou, Niki, Rosell, Rafael, Riess, Jonathan W, Nichols, Robert, Doebele, Robert C, Bivona, Trever G

Volltext

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer von Nanjo, Shigeki, Wu, Wei, Karachaliou, Niki, Blakely, Collin M, Suzuki, Junji, Chou, Yu-Ting, Ali, Siraj M, Kerr, D Lucas, Olivas, Victor R, Shue, Jonathan, Rotow, Julia, Mayekar, Manasi K, Haderk, Franziska, Chatterjee, Nilanjana, Urisman, Anatoly, Yeo, Jia Chi, Skanderup, Anders J, Tan, Aaron C, Tam, Wai Leong, Arrieta, Oscar, Hosomichi, Kazuyoshi, Nishiyama, Akihiro, Yano, Seiji, Kirichok, Yuriy, Tan, Daniel Sw, Rosell, Rafael, Okimoto, Ross A, Bivona, Trever G

Volltext

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance von Blakely, Collin M, Bivona, Trever G

Volltext

A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations von Blakely, Collin M

Volltext

Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small cell lung cancer von Woodard, Gavitt A., MD, Wang, Sue X., BS, Kratz, Johannes R., MD, Zoon-Besselink, Clara T., BS, Chiang, Chun-Yuan, MBBS, Gubens, Matthew A., MD, MS, Jahan, Thierry M., MD, Blakely, Collin M., MD, PhD, Jones, Kirk D., MD, Mann, Michael J., MD, Jablons, David M., MD

Volltext

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study von Ji, Jingran, Aredo, Jacqueline V., Piper-Vallillo, Andrew, Huppert, Laura, Rotow, Julia K., Husain, Hatim, Stewart, Susan, Cobb, Rosemary, Wakelee, Heather A., Blakely, Collin M., Wong, Melisa L., Gubens, Matthew A., Madani, Mohammad H., Digumarthy, Subba R., McCoach, Caroline, Piotrowska, Zofia, Neal, Joel W., Riess, Jonathan W.

Volltext

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials von Doebele, Robert C, Drilon, Alexander, Paz-Ares, Luis, Siena, Salvatore, Shaw, Alice T, Farago, Anna F, Blakely, Collin M, Seto, Takashi, Cho, Byung Chul, Tosi, Diego, Besse, Benjamin, Chawla, Sant P, Bazhenova, Lyudmila, Krauss, John C, Chae, Young Kwang, Barve, Minal, Garrido-Laguna, Ignacio, Liu, Stephen V, Conkling, Paul, John, Thomas, Fakih, Marwan, Sigal, Darren, Loong, Herbert H, Buchschacher, Gary L, Garrido, Pilar, Nieva, Jorge, Steuer, Conor, Overbeck, Tobias R, Bowles, Daniel W, Fox, Elizabeth, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Demetri, George D

Volltext

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer von Halliday, Patrick R., Blakely, Collin M., Bivona, Trever G.

Volltext

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing von Maynard, Ashley, McCoach, Caroline E., Rotow, Julia K., Harris, Lincoln, Haderk, Franziska, Kerr, D. Lucas, Yu, Elizabeth A., Schenk, Erin L., Tan, Weilun, Zee, Alexander, Tan, Michelle, Gui, Philippe, Lea, Tasha, Wu, Wei, Urisman, Anatoly, Jones, Kirk, Sit, Rene, Kolli, Pallav K., Seeley, Eric, Gesthalter, Yaron, Le, Daniel D., Yamauchi, Kevin A., Naeger, David M., Bandyopadhyay, Sourav, Shah, Khyati, Cech, Lauren, Thomas, Nicholas J., Gupta, Anshal, Gonzalez, Mayra, Do, Hien, Tan, Lisa, Bacaltos, Bianca, Gomez-Sjoberg, Rafael, Gubens, Matthew, Jahan, Thierry, Kratz, Johannes R., Jablons, David, Neff, Norma, Doebele, Robert C., Weissman, Jonathan, Blakely, Collin M., Darmanis, Spyros, Bivona, Trever G.

Volltext

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC von Lara, Matthew S., Gubens, Matthew A., Bacaltos, Bianca, Daran, Lea, Lim, Steffany L., Li, Tianhong, Gandara, David R., Bivona, Trever G., Riess, Jonathan W., Blakely, Collin M.

Volltext

Neoadjuvant oncogene-targeted therapy in early stage non-small cell lung cancer as a strategy to improve clinical outcome and identify early mechanisms of resistance von McCoach, Caroline E., MD PhD, Bivona, Trever G., MD PhD, Blakely, Collin M., MD PhD, Doebele, Robert C., MD PhD

Volltext

Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies von Blakely, Collin M., McCoach, Caroline E.

Volltext

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer von Gini, Beatrice, Thomas, Nicholas, Blakely, Collin M.

Volltext

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study von Yang, James Chih-Hsin, Reckamp, Karen L., Kim, Young-Chul, Novello, Silvia, Smit, Egbert F., Lee, Jong-Seok, Su, Wu-Chou, Akerley, Wallace L., Blakely, Collin M., Groen, Harry J.M., Bazhenova, Lyudmila, Carcereny Costa, Enric, Chiari, Rita, Hsia, Te-Chun, Golsorkhi, Tony, Despain, Darrin, Shih, Danny, Popat, Sanjay, Wakelee, Heather

Volltext

Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review von Blakely, Collin M., Weder, Walter, Bubendorf, Lukas, He, Jianxing, Majem, Margarita, Shyr, Yu, Chaft, Jamie E.

Volltext